DENTSPLY SIRONA grants equity awards to EVP Denti

DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards.

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards. On March 4, 2026, he was granted stock options for 270,200 shares and 59,524 shares of common stock through restricted stock units. Both the RSUs and options vest in one-third annual installments over three years, ending March 4, 2029. The options have an exercise price set at 110% of the company’s closing common stock price on the grant date, aligning the award’s value with future share performance.

Insider Trade Summary

Grant/Award: 329,724 shares

Grant/Award 2 txns

Insider Denti Aldo Mariano Roberto

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	270,200	$0.00	$0.00
Grant/Award	Common Stock	59,524	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 270,200 contracts (Direct); Common Stock — 59,524 shares (Direct)

Footnotes (2)

1. F1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.
2. F2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DENTSPLY SIRONA (XRAY) report for Aldo Denti?

DENTSPLY SIRONA reported equity awards to Aldo Mariano Roberto Denti. He received 270,200 stock options and 59,524 restricted stock units on March 4, 2026, as part of his compensation as EVP and Chief Commercial Officer.

How many stock options did Aldo Denti receive from DENTSPLY SIRONA (XRAY)?

Aldo Denti received stock options covering 270,200 shares of DENTSPLY SIRONA common stock. These options vest in equal one-third portions annually over three years, ending March 4, 2029, subject to the award’s standard terms and continued service.

What restricted stock unit grant did Aldo Denti receive at DENTSPLY SIRONA (XRAY)?

He received an award of 59,524 restricted stock units of DENTSPLY SIRONA common stock. The RSUs vest in one-third increments each year over a three-year period, with final vesting scheduled for March 4, 2029, if vesting conditions are met.

When do Aldo Denti’s new equity awards at DENTSPLY SIRONA (XRAY) fully vest?

Both the stock options and restricted stock units granted to Aldo Denti vest over three years. They vest in annual one-third installments, with the final tranche scheduled to vest on March 4, 2029, assuming continued eligibility under the award terms.

How is the exercise price determined for Aldo Denti’s DENTSPLY SIRONA (XRAY) stock options?

The exercise price for Aldo Denti’s stock options is set at 110% of DENTSPLY SIRONA’s closing common stock price on the March 4, 2026 grant date. This pricing structure links potential option value to future share price performance above that reference level.

Is Aldo Denti’s DENTSPLY SIRONA (XRAY) Form 4 a purchase or an award?

The Form 4 reflects equity awards, not open-market purchases. It reports a grant or award acquisition of 270,200 stock options and 59,524 restricted stock units to Aldo Denti as part of his executive compensation package at DENTSPLY SIRONA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denti Aldo Mariano Roberto

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		59,524(1)	A	$0	59,524	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.78	03/04/2026		A		270,200		03/04/2027(2)	03/04/2036	Common Stock	270,200	$0	270,200	D

Explanation of Responses:

1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

	/s/ Jessica Nielsen Causey, Attorney-In-Fact for Aldo Mariano Roberto Denti	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.